Ania Ramondo
Psychiatric/Mental Health · Richmond, VANPI 1972055853
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 283 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 27.5% of the total. 2025 is the largest year on record at $2,690, more than ten times the $154 reported in 2022. Among psychiatric/mental health clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$635
- AbbVie$486
- Neurocrine Biosciences, Inc.$451
- E.r. Squibb & Sons, L.L.C.$331
- plus $862 from 9 others
What the payments were for
- Food & beverage$5,09998%
- Education$1082%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 82 | $1,430 |
| Otsuka America Pharmaceutical, Inc. | 50 | $1,013 |
| Lundbeck LLC | 32 | $635 |
| AbbVie | 28 | $486 |
| Neurocrine Biosciences, Inc. | 18 | $451 |
| E.r. Squibb & Sons, L.L.C. | 21 | $331 |
| Alkermes, Inc. | 9 | $245 |
| Vanda Pharmaceuticals Inc. | 18 | $240 |
| Teva Pharmaceuticals USA, Inc. | 15 | $207 |
| Indivior Inc. | 3 | $60 |
| Sunovion Pharmaceuticals Inc. | 2 | $37 |
| Corium, LLC | 2 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Neurelis, Inc. | 1 | $14 |
| Tris Pharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,207 in reported general payments places this provider in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 22 | $2,124 |
| Divalproex Sodium ErDivalproex Sodium | 16 | $365 |
| Prazosin Hcl | 17 | $350 |
| Sertraline Hcl | 25 | $314 |
| Doxepin Hcl | 16 | $160 |
| Quetiapine Fumarate | 17 | $154 |
| Guanfacine Hcl ErGuanfacine Hcl | 13 | $111 |
| Trazodone Hcl | 16 | $110 |
| Clonidine Hcl | 16 | $63 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Richmond
- Tonjanika BoydRichmond$40K
- Kirby PatmonRichmond$36K
- Abbie SmithRichmond$14K
- Thomas MamalakisRichmond$12K
- Monica MeyerRichmond$11K
- Vicky SpillerRichmond$10K
- Kimberly Southam-GerowRichmond$8K
- Charles McDonoughRichmond$7K
- Nympha DalgadoRichmond$7K
- Justin RayChesapeake$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.